Swedencare AB (publ) (SECARE.ST)
SEK 48.8
(-2.4%)
SEK 48.8
(-2.4%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 58.6 Million SEK | -37.99% |
| 2022 | 94.5 Million SEK | 73.01% |
| 2021 | 54.62 Million SEK | 12.55% |
| 2020 | 48.53 Million SEK | 62.24% |
| 2019 | 29.91 Million SEK | 28.27% |
| 2018 | 23.32 Million SEK | 97.26% |
| 2017 | 11.82 Million SEK | 20.89% |
| 2016 | 9.77 Million SEK | 5.11% |
| 2015 | 9.3 Million SEK | 164.54% |
| 2014 | 3.51 Million SEK | 3412.22% |
| 2013 | 100.13 Thousand SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 20.9 Million SEK | -30.56% |
| 2024 Q1 | 30.1 Million SEK | 331.54% |
| 2024 Q3 | 24 Million SEK | 14.83% |
| 2023 Q1 | 17.2 Million SEK | 152.45% |
| 2023 FY | 58.6 Million SEK | -37.99% |
| 2023 Q2 | 16.3 Million SEK | -5.23% |
| 2023 Q3 | 38.1 Million SEK | 133.74% |
| 2023 Q4 | -13 Million SEK | -134.12% |
| 2022 Q1 | 11.53 Million SEK | 133.58% |
| 2022 FY | 94.5 Million SEK | 73.01% |
| 2022 Q3 | 24.28 Million SEK | -68.71% |
| 2022 Q4 | -32.79 Million SEK | -235.04% |
| 2022 Q2 | 77.62 Million SEK | 573.14% |
| 2021 Q2 | 32.59 Million SEK | 21.87% |
| 2021 Q3 | 29.63 Million SEK | -9.09% |
| 2021 Q4 | -34.34 Million SEK | -215.91% |
| 2021 Q1 | 26.74 Million SEK | 30.79% |
| 2021 FY | 54.62 Million SEK | 12.55% |
| 2020 Q3 | 14.49 Million SEK | 181.77% |
| 2020 Q2 | 5.14 Million SEK | -39.05% |
| 2020 FY | 48.53 Million SEK | 62.24% |
| 2020 Q4 | 20.44 Million SEK | 41.05% |
| 2020 Q1 | 8.44 Million SEK | 47.54% |
| 2019 Q3 | 8.87 Million SEK | 30.34% |
| 2019 Q2 | 6.8 Million SEK | -19.97% |
| 2019 Q1 | 8.5 Million SEK | 48.17% |
| 2019 FY | 29.91 Million SEK | 28.27% |
| 2019 Q4 | 5.72 Million SEK | -35.54% |
| 2018 Q1 | 4.8 Million SEK | 24.77% |
| 2018 Q3 | 6.96 Million SEK | 19.71% |
| 2018 Q4 | 5.74 Million SEK | -17.51% |
| 2018 FY | 23.32 Million SEK | 97.26% |
| 2018 Q2 | 5.81 Million SEK | 21.12% |
| 2017 Q3 | 3.16 Million SEK | 268.06% |
| 2017 Q4 | 3.84 Million SEK | 21.43% |
| 2017 FY | 11.82 Million SEK | 20.89% |
| 2017 Q1 | 3.94 Million SEK | 540.17% |
| 2017 Q2 | 861 Thousand SEK | -78.17% |
| 2016 Q1 | 3.29 Million SEK | 41.03% |
| 2016 Q4 | 616.09 Thousand SEK | -80.97% |
| 2016 Q3 | 3.23 Million SEK | 23.02% |
| 2016 Q2 | 2.63 Million SEK | -20.07% |
| 2016 FY | 9.77 Million SEK | 5.11% |
| 2015 Q1 | 1.8 Million SEK | 0.0% |
| 2015 FY | 9.3 Million SEK | 164.54% |
| 2015 Q4 | 2.33 Million SEK | 0.39% |
| 2015 Q2 | 2.84 Million SEK | 57.6% |
| 2015 Q3 | 2.32 Million SEK | -18.1% |
| 2014 FY | 3.51 Million SEK | 3412.22% |
| 2013 FY | 100.13 Thousand SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AcuCort AB | -13.69 Million SEK | 528.018% |
| AlzeCure Pharma AB (publ) | -37.16 Million SEK | 257.667% |
| BioGaia AB (publ) | 365.35 Million SEK | 83.961% |
| Enzymatica AB (publ) | -49.72 Million SEK | 217.841% |
| Enorama Pharma AB (publ) | -44.61 Million SEK | 231.352% |
| Gabather AB (publ) | -9.43 Million SEK | 720.96% |
| Klaria Pharma Holding AB (publ.) | -35.78 Million SEK | 263.76% |
| Moberg Pharma AB (publ) | -21.09 Million SEK | 377.817% |
| Nanexa AB (publ) | -76.39 Million SEK | 176.704% |
| Newbury Pharmaceuticals AB (publ) | -15.4 Million SEK | 480.396% |
| ODI Pharma AB | 355.97 Thousand SEK | -16362.015% |
| Orexo AB (publ) | -128.3 Million SEK | 145.674% |
| Probi AB (publ) | 16.81 Million SEK | -248.415% |
| Swedish Orphan Biovitrum AB (publ) | 2.4 Billion SEK | 97.567% |
| Toleranzia AB | -7.45 Million SEK | 885.628% |
| Vivesto AB | -367.03 Million SEK | 115.966% |